Insulin Lispro
Brand name: Humalog Kwikpen U-100
Rank #28 of 500 drugs by total cost
$623.9M
Total Cost
854,813
Total Claims
$623.9M
Total Cost
30,793
Prescribers
$730
Cost per Claim
141,554
Beneficiaries
1,393,348
30-Day Fills
$20K
Avg Cost/Provider
28
Avg Claims/Provider
About Insulin Lispro
Insulin Lispro (sold as Humalog Kwikpen U-100) was prescribed 854,813 times by 30,793 Medicare Part D providers in 2023, costing the program $623.9M. At $730 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
| 27 | Linaclotide (Linzess) | $639.4M | 823,023 |
| 28 | Insulin Lispro (Humalog Kwikpen U-100) | $623.9M | 854,813 |
| 29 | Dupilumab (Dupixent Pen) | $609.1M | 156,267 |
| 30 | Rsvpref3 Antigen/As01e/Pf (Arexvy) | $608.6M | 1,935,431 |
| 31 | Pomalidomide (Pomalyst) | $589.0M | 27,253 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology